HPGC Renmintongtai Pharmaceutical Corporation(600829.SS)
No price history available.
Key financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CNYm | 8,005 | 9,315 | 9,641 | 10,390 | 10,048 | 10,379 | N/A | N/A |
| Operating profit | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | CNYm | 145 | 277 | 264 | 292 | 213 | 134 | N/A | N/A |
| EPS reported | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
HPGC Renmintongtai Pharmaceutical Corporation is a pharmaceutical enterprise actively involved in the wholesale and retail distribution of diverse medicinal products across China and internationally. Its extensive product portfolio encompasses traditional Chinese medicines, herbal remedies, chemical preparations, antibiotics, biologics, biochemical drugs, medical equipment, and health-related items. The company also extends its operations to include logistics services, specifically warehousing and distribution. Additionally, it offers comprehensive hospital services covering medical treatment, scientific research, disease prevention, health promotion, rehabilitation, blood purification, and renal disease management. Through its e-commerce platform, HPGC Renmintongtai markets a broad selection of items, including Chinese and Western pharmaceuticals, traditional Chinese herbs, nutritional supplements, medical devices, cosmetics, and everyday necessities. The company maintains a significant retail presence with 319 chain stores located throughout Heilongjiang Province. Established in 1950 and headquartered in Harbin, China, HPGC Renmintongtai Pharmaceutical Corporation operates as a subsidiary of Harbin Pharmaceutical Group Co., Ltd.
Similar companies
- Jiangsu Jibeier Pharmaceutical Co., Ltd.
- Suven Life Sciences Limited
- Luoxin Pharmaceuticals Group Stock Co., Ltd.
- China Shineway Pharmaceutical Group Limited
- Shenzhen Neptunus Bioengineering Co., Ltd.
- Sun Pharma Advanced Research Company Limited
- Teyi Pharmaceutical Group Co.,Ltd
- Zhejiang AngLiKang Pharmaceutical CO.,LTD.
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
HPGC Renmintongtai Pharmaceutical Corporation (600829.SS)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
HPGC Renmintongtai Pharmaceutical Corporation is a pharmaceutical enterprise actively involved in the wholesale and retail distribution of diverse medicinal products across China and internationally. Its extensive product portfolio encompasses traditional Chinese medicines, herbal remedies, chemical preparations, antibiotics, biologics, biochemical drugs, medical equipment, and health-related items. The company also extends its operations to include logistics services, specifically warehousing and distribution. Additionally, it offers comprehensive hospital services covering medical treatment, scientific research, disease prevention, health promotion, rehabilitation, blood purification, and renal disease management. Through its e-commerce platform, HPGC Renmintongtai markets a broad selection of items, including Chinese and Western pharmaceuticals, traditional Chinese herbs, nutritional supplements, medical devices, cosmetics, and everyday necessities. The company maintains a significant retail presence with 319 chain stores located throughout Heilongjiang Province. Established in 1950 and headquartered in Harbin, China, HPGC Renmintongtai Pharmaceutical Corporation operates as a subsidiary of Harbin Pharmaceutical Group Co., Ltd.
- Jiangsu Jibeier Pharmaceutical Co., Ltd.
- Suven Life Sciences Limited
- Luoxin Pharmaceuticals Group Stock Co., Ltd.
- China Shineway Pharmaceutical Group Limited
- Shenzhen Neptunus Bioengineering Co., Ltd.
- Sun Pharma Advanced Research Company Limited
- Teyi Pharmaceutical Group Co.,Ltd
- Zhejiang AngLiKang Pharmaceutical CO.,LTD.